Tscan Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
4.5%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$7.6Mnext fiscal year
FY EPS (est.)
-$0.84next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| TSC-102-A01 and TSC-102-A03 Phase 1 Trial Launch | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway QuarterlyTarget: Second half of 2027
TSC-101 Manufacturing Process Duration Annually1,200.0%Target: 12 days
Watch Items
- TSC-101 Phase 3 Trial (ALLOHA-2) InitiationTrigger: Initiation of patient dosingAction: Monitor clinical trial registry updates and company press releases for the official launch of the registrational study.
- Cohort C Clinical Data from ALLOHA Phase 1 TrialTrigger: Release of early clinical dataAction: Evaluate relapse-free survival, donor chimerism, and safety profile of patients treated with the commercial-ready manufacturing process.
- TSC-102-A01 and TSC-102-A03 Phase 1 Trial InitiationTrigger: First patient dosedAction: Track the planned initiation of the Phase 1 study in the second half of 2026.
Research as of 19 Jun 2026